Journal
ANNALS OF ONCOLOGY
Volume 21, Issue 6, Pages 1203-1210Publisher
OXFORD UNIV PRESS
DOI: 10.1093/annonc/mdp484
Keywords
immune reconstitution; lymphoma; rituximab; transplantation
Categories
Funding
- National Cancer Institute Lymphoma SPORE [P50 CA09688]
- National Institutes of Health [K23 CA124465]
- Genentech/Biogen Idec
- Immunex Corporation
- Nexell Therapeutics, Inc.
Ask authors/readers for more resources
Background: Rituximab may improve transplant outcomes but may delay immunologic recovery. Patients and methods: Seventy-seven patients with low-grade or mantle cell lymphoma received autologous stem-cell transplantation (ASCT) on a phase II study. Rituximab 375 mg/m(2) was administered 3 days before mobilization-dose cyclophosphamide, then weekly for four doses after count recovery from ASCT. Immune reconstitution was assessed. Results: Sixty percent of transplants occurred in first remission. Actuarial event-free survival (EFS) and overall survival (OS) were 60% and 73%, respectively, at 5 years, with 7.2-year median follow-up for OS in surviving patients. Median EFS was 8.3 years. Older age and transformed lymphomas were independently associated with inferior EFS, whereas day 60 lymphocyte counts did not predict EFS or late infections. Early and late transplant-related mortality was 1% and 8%, with secondary leukemia in two patients. B-cell counts recovered by 1-2 years; however, the median IgG level remained low at 2 years. Late-onset idiopathic neutropenia, generally inconsequential, was noted in 43%. Conclusion: ASCT with rituximab can produce durable remissions on follow-up out to 10 years. Major infections do not appear to be significantly increased or to be predicted by immune monitoring.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available